Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors

Journal of Gene Medicine

Volumn 4, Issue 3, 2002, Pages 229-239

  Sena Esteves, Miguel ^a,b   Hampl, Jürgen A ^a   Camp, Sara M ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Gene therapy; HSV amplicons; Hybrid vectors; Packaging lines; Retroviral vectors

Indexed keywords

BETA GALACTOSIDASE; GAG PROTEIN; GENE PRODUCT; POL PROTEIN; RETROVIRUS VECTOR; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

AMPLICON; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLIOMA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL STRAIN 3T3; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE THERAPY; GENE VECTOR; GENETICS; MOUSE; NORTHERN BLOTTING; PHYSIOLOGY; VIRUS ASSEMBLY;

CANIS FAMILIARIS; HERPES; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

3T3 CELLS; ANIMALS; BLOTTING, NORTHERN; CELL LINE; GENE AMPLIFICATION; GENE THERAPY; GENETIC VECTORS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MOLONEY MURINE LEUKEMIA VIRUS; RNA, VIRAL; SIMPLEXVIRUS; TRANSDUCTION, GENETIC; VIRUS ASSEMBLY;

EID: 0036581542     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.276     Document Type: Article

References (66)

1. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
2. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
3. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci 1990; 87: 2211-2215.
4. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
5. Blaese RM, Anderson WF. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327-329.
6. Sena-Esteves M, Aghi M, Pechan PA, et al. Gene delivery to the nervous system using retroviral vectors. In Genetic Manipulation of the Nervous System, Latchman DS (ed.), Academic Press: London, 1995; 149-180.
7. Short MP, Choi BC, Lee JK, et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-439.
8. Douar A-M, Adebakin S, Themis M, et al. Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther 1997; 4: 883-890.
9. Nelson DM, Metzger ME, Donahue RE, et al. In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning. Hum Gene Ther 1997; 8: 747-754.
10. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
11. Takamiya Y, Short MP, Moolten FL, et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79: 104-110.
12. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
13. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 10: 2325-2335.
14. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
15. Tamiya T, Wei MX, Chase M, et al. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producing cells. Gene Ther 1995; 2: 531-538.
16. Tamura M, Shimizu K, Yamada M, et al. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum Gene Ther 1997; 8: 381-391.
17. Yoshii Y, Maki Y, Tsuboi K, et al. Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors. J Neurosurg 1986; 65: 659-663.
18. Harsh GR, Deisboeck TS, Louis DN, et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000; 92 804-811.
19. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
20. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
21. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 1988; 85: 6460-6464.
22. Markowitz D, Goff S, Bank A. Construction of a safe and efficient retrovirus packaging cell line. Adv Exp Med Biol 1988; 241: 35-40.
23. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
24. Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nat Med 1997; 3: 964-969.
25. Rother RP, Fodor WL, Springhorn JP, et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
26. Takeuchi Y, Porter CD, Strahan KM, et al. Sensitization of cells and retroviruses to human serum by alpha(1-3) galactosyl-transferase. Nature 1996; 379: 85-88.
27. Hatzoglou M, Hodgson CP, Mularo F, et al. Efficient packaging of a specific VL30 retroelement by psi 2 cells which produce MoMLV recombinant retroviruses. Hum Gene Ther 1990; 1: 385-397.
28. Scadden DT, Fuller B, Cunningham JM. Human cells infected with retrovirus vectors acquire an endogenous murine provirus. J Virol 1990; 64: 424-427.
29. Chakraborty AK, Zink MA, Hodgson CP. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy. Cancer Gene Ther 1994; 1: 113-118.
30. Pear WS, Nolan GP, Scott ML, et al. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 1993; 90: 8392-8396.
31. Cosset F-L, Takeuchi Y, Battini J-L, et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
32. Rigg RJ, Chen J, Dando JS, et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 1996; 218: 290-295.
33. Davis JL, Witt RM, Gross PR, et al. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther 1997; 8: 1459-1467.
34. Bauer G, Sauter S, Ibanez C, et al. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line. Biol Blood Marrow Transplant 1998; 4: 119-127.
35. Patience C, Takeuchi Y, Cosset F-L, et al. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J Virol 1998; 72: 2671-2676.
36. Pedersen PH, Marienhagen K, Mork S, et al. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res 1993; 53: 5158-5165.
37. Lal B, Indurti RR, Couraud PO, et al. Endothelial cell implantation and survival within experimental gliomas. Proc Natl Acad Sci U S A 1994; 91: 9695-9699.
38. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 2000; 97: 12846-12851.
39. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 1992; 66: 5110-5113.
40. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
41. Naviaux RK, Costanzi E, Haas M, et al. The pCL system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996; 70: 5701-5705.
42. Noguiez-Hellin P, Robert-LeMeur M, Salzmann J-L, et al. Plasmoviruses: nonviral/viral vectors for gene therapy. Proc Natl Acad Sci U S A 1996; 93: 4175-4180.
43. Savard N, Cosset FL, Epstein AL. Defective herpes simplex virus type 1 vectors harboring gag, pol and env genes can be used to rescue defective retrovirus vectors. J Virol 1997; 71: 4111-4117.
44. Sena-Esteves M, Saeki Y, Camp SM, et al. Single-step conversion of cells to retrovirus vector producers with HSV/EBV hybrid amplicons. J Virol 1999; 73: 10426-10439.
45. Li K-J, Garoff H. Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors. Proc Natl Acad Sci U S A 1996; 93: 11658-11663.
46. Feng MWH, Jackson J, Goldman CK, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
47. Yoshida Y, Emi N, Hamada H. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun 1997; 232: 379-382.
48. Lin X. Construction of new retroviral producer cells from adenoviral and retroviral vectors. Gene Ther 1998; 5: 1251-1258.
49. Ramsey WJ, Caplen NJ, Li Q, et al. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors. Biochem Biophys Res Commun 1998; 246: 912-919.
50. Caplen NJ, Higginbotham JN, Scheel JR, et al. Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther 1999; 6: 454-459.
51. Duisit G, Salvetti A, Moullier P, et al. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999; 10: 189-200.
52. Johnston KM, Jacoby DR, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther 1997; 8: 359-370.
53. Fraefel C, Jacoby DR, Lage C, et al. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3: 813-825.
54. Costantini LC, Jacoby DR, Wang S, et al. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 1999; 10: 2481-2494.
55. Smith IL, Hardwicke MA, Sandri-Goldin RM. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992; 186: 74-86.
56. Berens ME, Bjotvedt G, Levesque DC, et al. Tumorigenic, invasive, karyotipic, and immunocytochemical characteristics of clonal cell lines derived from a spontaneous canine anaplastic astrocytoma. In Vitro Cell Dev Biol Anim 1993; 29A: 310-318.
57. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
58. Bender MA, Palmer TD, Gelinas RE, et al. Evidence that the packaging signal of Moloney leukemia virus extends into the gag region. J Virol 1987; 61: 1639-1646.
59. Karacostas V, Wolffe EJ, Nagashima K, et al. Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193: 661-671.
60. Ledoux JM, Morgan JR, Snow RG, et al. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996; 70: 6468-6473.
61. Vogt VM. Ubiquitin in retrovirus assembly: actor or bystander? Proc Natl Acad Sci U S A 2000; 97: 12945-12947.
62. Garrus JE, von Schwedler UK, Pornillos OW, et al. Tsg101 and the vacuolar protein sorting pathway are essential for hiv-1 budding. Cell 2001; 107: 55-65.
63. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002; 415: 88-92.
64. Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374: 367-370.
65. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural progenitor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000; 1: 347-357.
66. Yamada M, Shimizu K, Miyao Y, et al. Migration of genetically labeled glioma cells after implantation into murine brain. J Neurosci Res 1994; 38: 415-423.